TRVI

Trevi Therapeutics (TRVI)

About Trevi Therapeutics (TRVI)

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Details

Daily high

$6.62

Daily low

$6.36

Price at open

$6.52

52 Week High

$7.39

52 Week Low

$2.30

Market cap

625.5M

Dividend yield

0.00%

Volume

3.7M

Avg. volume

4.4M

P/E ratio

-13.76

Trevi Therapeutics News